ライフサイエンスコーパス: psoriatic arthritis

1 ncestry with multiple cases of psoriasis and psoriatic arthritis.

2 kinumab efficacy and safety for treatment of psoriatic arthritis.

3 l symptoms and pathological joint changes of psoriatic arthritis.

4 being developed to characterize and stratify psoriatic arthritis.

5 sease, and a seronegative arthritis known as psoriatic arthritis.

6 ce has accrued in ankylosing spondylitis and psoriatic arthritis.

7 uality of life in ankylosing spondylitis and psoriatic arthritis.

8 tor inhibitors in ankylosing spondylitis and psoriatic arthritis.

9 the treatment of ankylosing spondylitis and psoriatic arthritis.

10 n protein, is FDA approved for psoriasis and psoriatic arthritis.

11 statistical significance in the treatment of psoriatic arthritis.

12 s is most apparent in juvenile arthritis and psoriatic arthritis.

13 atment of psoriasis and have been studied in psoriatic arthritis.

14 sociated with both early-onset psoriasis and psoriatic arthritis.

15 is under investigation for the treatment of psoriatic arthritis.

16 en shown equally in rheumatoid arthritis and psoriatic arthritis.

17 thritis appears to be strongly suggestive of psoriatic arthritis.

18 nsitive and quantitatively discriminative in psoriatic arthritis.

19 al models and human rheumatoid arthritis and psoriatic arthritis.

20 c modifiers such as CARD15 may predispose to psoriatic arthritis.

21 s also have joint involvement, indicative of psoriatic arthritis.

22 ies of patients with rheumatoid arthritis or psoriatic arthritis.

23 nd 20-30% of individuals with psoriasis have psoriatic arthritis.

24 recently, was licensed for the treatment of psoriatic arthritis.

25 ors, thereby contributing to pathogenesis of psoriatic arthritis.

26 f RA and, more recently, for juvenile RA and psoriatic arthritis.

27 , and idiopathic inflammatory arthritis), or psoriatic arthritis.

28 n used to distinguish between rheumatoid and psoriatic arthritis.

29 r the experimental approach to mechanisms in psoriatic arthritis.

30 ic susceptibility may underlie psoriasis and psoriatic arthritis.

31 s most significant in those families without psoriatic arthritis.

32 used more often and earlier, particularly in psoriatic arthritis.

33 verity of pruritus, burning, joint pain, and psoriatic arthritis.

34 and patients with ankylosing spondylitis and psoriatic arthritis.

35 ant in the development of conditions such as psoriatic arthritis.

36 hese approaches have not yet been studied in psoriatic arthritis.

37 ne that is implicated in the pathogenesis of psoriatic arthritis.

38 veitis, mild psoriasis, severe psoriasis, or psoriatic arthritis.

39 in-17A monoclonal antibody, in patients with psoriatic arthritis.

40 -17A receptor improved signs and symptoms of psoriatic arthritis.

41 sis of uveitis for the risk for psoriasis or psoriatic arthritis.

42 improved response rates among patients with psoriatic arthritis.

43 ebo-controlled study involving patients with psoriatic arthritis.

44 er investigation of ustekinumab's effects on psoriatic arthritis.

45 icacy of ustekinumab in patients with active psoriatic arthritis.

46 s erythematosus, 20 with vasculitis, 18 with psoriatic arthritis, 16 with scleroderma, and 261 with v

47 1 %), joint pain (69%), arthritis (51%), and psoriatic arthritis (20%).

48 ients with seropositive RA, 11 patients with psoriatic arthritis, 20 normal controls, and 9 affected

49 (371 person-years), and 2,498 patients with psoriatic arthritis (618 person-years).

50 Among 5604 patients with psoriasis and psoriatic arthritis, 92.4% had seen at least 1 physician

51 Many patients with psoriasis develop psoriatic arthritis, a chronic inflammatory disease that

52 riasis (and 1 who also developed features of psoriatic arthritis) after receiving rituximab for a var

53 ritis and the group with mild psoriasis with psoriatic arthritis also had an increased risk of incide

54 ely effective for ankylosing spondylitis and psoriatic arthritis, although the large placebo response

55 e lack of agreed classification criteria for psoriatic arthritis; although in both adult and juvenile

56 with RA and 3 with seronegative SpA (2 with psoriatic arthritis and 1 with ankylosing spondylitis) w

57 Five children with uveitis and psoriatic arthritis and 1 with uveitis and psoriasis Obs

58 We identified 74,129 cases of psoriasis and psoriatic arthritis and 13,114 cases of uveitis.

59 psoriasis (including 10107 with concomitant psoriatic arthritis and 137847 without psoriatic arthrit

60 for treatment of two spondyloarthropathies, psoriatic arthritis and ankylosing spondylitis.

61 is integral to the pathologies of psoriasis, psoriatic arthritis and Crohn's disease.

62 significantly reduced signs and symptoms of psoriatic arthritis and diminished skin lesions compared

63 is only infrequently found in patients with psoriatic arthritis and healthy controls.

64 The presentation of uveitis in psoriatic arthritis and inflammatory bowel disease diffe

65 ritis, undifferentiated spondyloarthropathy, psoriatic arthritis and juvenile spondyloarthropathy.

66 eye symptoms in patients with psoriasis and psoriatic arthritis and on skin and joint symptoms in pa

67 ets interleukin-17A, in patients with active psoriatic arthritis and previous inadequate response to

68 Etanercept offers patients with psoriatic arthritis and psoriasis a new therapeutic opti

69 Psoriatic arthritis and psoriasis are disease states in

70 Therefore, psoriatic arthritis and psoriasis may be appropriate the

71 STAT-3) were reported that have features of psoriatic arthritis and psoriasis respectively.

72 s injections) or placebo in 60 patients with psoriatic arthritis and psoriasis.

73 Moreover, psoriatic arthritis and rheumatoid arthritis synovium ha

74 ic studies did not find associations between psoriatic arthritis and several class I major histocompa

75 The group with severe psoriasis without psoriatic arthritis and the group with mild psoriasis wi

76 n 2.9 ng/ml, IQR 0.9 ng/ml) of patients with psoriatic arthritis and the plasma of healthy control su

77 progression of radiographic joint damage in psoriatic arthritis and to attenuate spinal inflammation

78 inflammatory features, such as enthesitis in psoriatic arthritis and uveitis in ankylosing spondyliti

79 e signs and symptoms of patients with active psoriatic arthritis and who had previously inadequate re

80 itant psoriatic arthritis and 137847 without psoriatic arthritis) and 147954 nonpsoriatic controls.

81 I patients (12 rheumatoid arthritis [RA], 12 psoriatic arthritis, and 12 systemic sclerosis) were rec

82 heumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and juvenile idiopathic arthritis a

83 r than RA, including ankylosing spondylitis, psoriatic arthritis, and polymyositis, in 36 patients.

84 was recently approved to treat psoriasis and psoriatic arthritis, and related agents are in clinical

85 consideration of the extent of skin disease, psoriatic arthritis, and severity of nail disease with c

86 tients with rheumatoid arthritis, those with psoriatic arthritis, and those with ankylosing spondylit

87 Psoriasis, psoriatic arthritis, and uveitis are inflammatory disord

88 asis, Crohn's disease, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-infecti

89 older with rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, or inflamma

90 ogenesis, enthesitis, and bone resorption in psoriatic arthritis are discussed.

91 ased focus on the diagnosis and treatment of psoriatic arthritis as newer and more effective drugs th

92 Recognition of the immunopathogenesis of psoriatic arthritis, as with rheumatoid arthritis and ps

93 ts had idiopathic anterior uveitis and 1 had psoriatic arthritis-associated anterior uveitis.

94 ntly increased in frequency in patients with psoriatic arthritis, but not in those with psoriasis.

95 KIR2DS2 genes are susceptible to developing psoriatic arthritis, but only when HLA ligands for their

96 dered understanding of disease mechanisms in psoriatic arthritis, but recent studies have provided in

97 Uveitis has been associated with psoriatic arthritis, but to our knowledge, the relations

98 ammation and specifically the development of psoriatic arthritis by impeding the Adam17-mediated rele

99 Spinal involvement in psoriatic arthritis can be asymptomatic, as in classical

100 lassified according to the Classification of Psoriatic Arthritis (CASPAR) criteria.

101 Ustekinumab significantly improved active psoriatic arthritis compared with placebo, and might off

102 A total of 5604 patients with psoriasis or psoriatic arthritis completed the survey.

103 for Research and Assessment of Psoriasis and Psoriatic Arthritis Composite Exercise cohort was used f

104 Clinicians generally agree that psoriatic arthritis constitutes a discreet subset within

105 Tight control of psoriatic arthritis disease activity through a treat-to-

106 at Fhl2-deficient mice develop a more severe psoriatic arthritis disease under induction of the induc

107 Since some patients with psoriatic arthritis do not respond to typical drug treat

108 Psoriatic arthritis endpoints included the proportion of

109 dramatically with ustekinumab therapy while psoriatic arthritis flared.

110 years or older, had a confirmed diagnosis of psoriatic arthritis for at least 6 months, and had a pre

111 Diagnosis of mild or severe psoriasis or psoriatic arthritis for uveitis risk and diagnosis of uv

112 from that seen in a comparison psoriasis and psoriatic arthritis group.

113 merica, and Asia-Pacific, adults with active psoriatic arthritis (>/=5 tender and >/=5 swollen joints

114 nd that the group with severe psoriasis with psoriatic arthritis had the greatest risk of incident uv

115 or antagonists in ankylosing spondylitis and psoriatic arthritis has generated considerable enthusias

116 for patients with ankylosing spondylitis and psoriatic arthritis has had a tremendous impact on daily

117 Psoriatic arthritis has histopathologic features that ar

118 The success of biologic agents in psoriatic arthritis has sparked great interest in this d

119 Currently available criteria for psoriatic arthritis have been evaluated in a large cohor

120 , psoriasis (HR 0.58 [95% CI 0.10-3.31]), or psoriatic arthritis (HR 0.74 [95% CI 0.20-2.76]) during

121 Presence of psoriatic arthritis (HR 0.82; 95% CI: 0.71-0.96) was a p

122 umatoid arthritis in 3.9%, and psoriasis and psoriatic arthritis in (6.3%) [corrected], atopy (allerg

123 .0008 compared to expected age of onset for psoriatic arthritis in childhood).

124 The more severe pathogenesis of psoriatic arthritis in Fhl2 knockout mice coincided with

125 the incidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric sur

126 Rigorously ascertained cases of psoriatic arthritis in subjects presenting to a rheumato

127 biologic groups (eg, a higher prevalence of psoriatic arthritis in the infliximab cohort).

128 randomly sampled patients with psoriasis and psoriatic arthritis in the US population from a database

129 s the efficacy and safety of ustekinumab for psoriatic arthritis in this phase II study.

130 Psoriasis and psoriatic arthritis inflict significant morbidity.

131 and adaptive immunity and are reminded that psoriatic arthritis is a systemic disease.

132 Psoriatic arthritis is an inflammatory arthritis associa

133 Psoriatic arthritis is an interesting MHC class I allele

134 Research into the pathophysiology of psoriatic arthritis is at an early, yet promising stage.

135 The incidence of psoriatic arthritis is currently estimated at 7 to 42% o

136 hase 2 trial of ustekinumab for treatment of psoriatic arthritis, joint disease improved.

137 er, increased body mass index, nail disease, psoriatic arthritis, larger plaques, more body sites, an

138 adult patients (aged >/=18 years) with early psoriatic arthritis (<24 months symptom duration), who h

139 oval by the Food and Drug Administration for psoriatic arthritis management are safe and effective in

140 Unmanaged psoriatic arthritis may result in progressive radiologic

141 t that the uveitis that accompanies juvenile psoriatic arthritis might be a distinct disease that is

142 , juvenile chronic arthritis (JCA) (n = 13), psoriatic arthritis (n = 9), rheumatoid arthritis (RA) (

143 ion, dyslipidemia, type 2 diabetes mellitus, psoriatic arthritis, nonalcoholic fatty liver disease, d

144 nkylosing spondylitis, and two patients with psoriatic arthritis, only one of whom was infected with

145 ype of the uveitis that accompanies juvenile psoriatic arthritis or psoriasis.

146 s that resulted in disabling flares of known psoriatic arthritis or unmasked previously occult joint

147 ase (OR 0.81 [95% CI 0.70-0.94]; p < 0.005), psoriatic arthritis (OR 1.36 [95% CI 1.00-1.84]; p < 0.0

148 ammatory bowel disease (IBD), and psoriasis, psoriatic arthritis, or ankylosing spondylitis (psoriasi

149 tient-years (95% CI, 2.8-7.0) for psoriasis, psoriatic arthritis, or ankylosing spondylitis.

150 comes were incident (new-onset) psoriasis or psoriatic arthritis, or progression to severe psoriasis.

151 d inflammatory conditions such as psoriasis, psoriatic arthritis, or rheumatoid arthritis.

152 sting efficacy for both plaque psoriasis and psoriatic arthritis, our case series raises concern that

153 ndividuals (P < 0.0001) and in patients with psoriatic arthritis (P = 0.004).

154 Psoriatic arthritis pathogenesis is incompletely underst

155 Confirmation was sought in 199 psoriasis and psoriatic arthritis patients from Toronto who were follo

156 fectively relieved the signs and symptoms of psoriatic arthritis patients in phase III trials.

157 fluid from RA and OA patients compared with psoriatic arthritis patients, whereas RNase activity of

158 ted to be reduced in the peripheral blood of psoriatic arthritis patients.

159 nes determine quantitative traits within the psoriatic arthritis phenotype.

160 ses, including systemic lupus erythematosus, psoriatic arthritis, polymyalgia rheumatica (PMR), giant

161 us on chromosome 16 are also associated with psoriatic arthritis, providing support for a model invol

162 n this double-blind study, 127 patients with psoriatic arthritis (PsA) and active psoriasis were rand

163 joint arthropathy is characteristic of both psoriatic arthritis (PsA) and osteoarthritis (OA), but t

164 examine its pathophysiologic significance in psoriatic arthritis (PsA) and rheumatoid arthritis (RA).

165 erging treatments and treatment paradigms of psoriatic arthritis (PsA) and spondyloarthritis (SpA).

166 n in synovial membrane (SM) of patients with psoriatic arthritis (PsA) compared with that in skin of

167 Psoriatic arthritis (PsA) has a large genetic component

168 Psoriatic arthritis (PsA) in children is clinically hete

169 Psoriatic arthritis (PsA) is a chronic inflammatory arth

170 Psoriatic arthritis (PsA) is a chronic inflammatory join

171 Psoriatic arthritis (PsA) is an inflammatory joint disea

172 Psoriatic arthritis (PsA) provides an ideal disease mode

173 in reducing the signs and symptoms of active psoriatic arthritis (PsA) through week 24 of the GO-REVE

174 f patients with RA, osteoarthritis (OA), and psoriatic arthritis (PsA) to determine OPN-R, OPN-L, and

175 ing receptors were susceptible to developing psoriatic arthritis (PsA), an effect that was strongest

176 to 30% of people with PsV eventually develop psoriatic arthritis (PsA), an inflammatory musculoskelet

177 arly rheumatoid arthritis (RA), 12 had early psoriatic arthritis (PsA), and 10 had osteoarthritis (OA

178 Both psoriasis and psoriatic arthritis (PsA), and by implication psoriatic

179 Psoriasis (PS), psoriatic arthritis (PsA), and chronic periodontitis (CP

180 enile idiopathic arthritis (JIA), psoriasis, psoriatic arthritis (PsA), and multiple sclerosis (MS),

181 thritis (OA), juvenile idiopathic arthritis, psoriatic arthritis (PsA), and RA were quantified by enz

182 nifestations of ankylosing spondylitis (AS), psoriatic arthritis (PsA), and reactive arthritis (ReA;

183 r incident liver disease in psoriasis (PsO), psoriatic arthritis (PsA), and rheumatoid arthritis (RA)

184 y effective in rheumatoid arthritis (RA) and psoriatic arthritis (PsA), but a significant number of p

185 patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), but not osteoarthritis (OA),

186 s' diagnosis of ankylosing spondylitis (AS), psoriatic arthritis (PsA), or reactive arthritis (ReA):

187 rms of arthritis (rheumatoid arthritis (RA), psoriatic arthritis (PsA), osteoarthritis (OA)) or chron

188 ternational diagnostic standard for juvenile psoriatic arthritis (PsA), replacing the less-restrictiv

189 sphodiesterase-4, in the treatment of active psoriatic arthritis (PsA).

190 luence the development of psoriasis (Ps) and psoriatic arthritis (PsA).

191 s are also associated with susceptibility to psoriatic arthritis (PsA).

192 RD15, was demonstrated to be associated with psoriatic arthritis (PsA).

193 ared with placebo in the treatment of active psoriatic arthritis (PsA).

194 ing antirheumatic drugs in the management of psoriatic arthritis (PsA).

195 he articular and cutaneous manifestations of psoriatic arthritis (PsA).

196 risk of two major clinical subtypes of PsV, psoriatic arthritis (PsA; n = 3,038) and cutaneous psori

197 Psoriatic arthritis (PsoA) was diagnosed in 25 of the in

198 ariables included age, sex, body mass index, psoriatic arthritis, psychiatric disorders, and comorbid

199 a seronegative spondyloarthropathy, such as psoriatic arthritis, reactive arthritis, or ankylosing s

200 spondyloarthropathy (ankylosing spondylitis, psoriatic arthritis, reactive arthritis, undifferentiate

201 18-86 years) with psoriasis, with or without psoriatic arthritis, receiving conventional IT and/or bi

202 ndertreatment of patients with psoriasis and psoriatic arthritis remain a significant problem in the

203 e with mild psoriasis, severe psoriasis, and psoriatic arthritis, respectively.

204 1) for mild psoriasis, severe psoriasis, and psoriatic arthritis, respectively.

205 oriasis, and 3.77 (2.66-5.34 [P < .001]) for psoriatic arthritis, respectively.

206 s with mild psoriasis, severe psoriasis, and psoriatic arthritis, respectively.

207 Patients with psoriasis and psoriatic arthritis respond well to tumor necrosis facto

208 luded the proportion of patients who met the Psoriatic Arthritis Response Criteria (PsARC) and who me

209 All three loci were also associated with psoriatic arthritis (rs4795067, combined P = 1 x 10; rs1

210 nd 150 mg improved the signs and symptoms of psoriatic arthritis, suggesting that secukinumab is a po

211 he major histocompatibility complex (MHC) to psoriatic arthritis susceptibility resembles that in pso

212 that B*38:01 and B*08 may be associated with psoriatic arthritis susceptibility, and that allotypes e

213 developed and cross-sectional evaluations of psoriatic arthritis synovia in the context of other arth

214 Fresh looks at psoriatic arthritis synovia suggest similarity to rheuma

215 to rheumatoid arthritis are being applied to psoriatic arthritis synovia.

216 othelial growth factor and angiopoietin 2 in psoriatic arthritis synovial vasculature may provide ins

217 metalloproteinases are strongly expressed in psoriatic arthritis synovium, and serum matrix metallopr

218 l inspection of RA, osteoarthritis (OA), and psoriatic arthritis synovium, exRNA was detectable only

219 port for distinct pathogenetic mechanisms in psoriatic arthritis that arise from a complex interplay

220 In patients with psoriatic arthritis, the frequency of C*06:02 was lower

221 Extrapolating from studies on adults with psoriatic arthritis, the mechanism of older-onset PsJIA

222 r positivity does not exclude a diagnosis of psoriatic arthritis--the single most important clinical

223 Newer trials in psoriatic arthritis therapy demonstrate ongoing ability

224 We randomly assigned patients with active psoriatic arthritis to receive brodalumab (140 or 280 mg

225 Ustekinumab is approved for psoriasis and psoriatic arthritis treatment and has been successfully

226 tanercept slowed radiographic progression in psoriatic arthritis trials, but it is not known whether

227 Psoriatic arthritis, undifferentiated arthritis, and spo

228 assess the effect of tight control on early psoriatic arthritis using a treat-to-target approach.

229 incident uveitis with mild psoriasis without psoriatic arthritis was not identified (adjusted hazard

230 Despite the 40 years since psoriatic arthritis was recognized, controversy still ex

231 human stratum corneum found in patients with psoriatic arthritis was shown to be different from AKA.

232 Adjusted HRs of psoriatic arthritis were 0.29 (95% CI, 0.12-0.71) and 0.

233 ts with psoriasis and 45.5% of patients with psoriatic arthritis were dissatisfied with their treatme

234 Studies of psoriatic arthritis were excluded.

235 A, adults (aged >/=18 years old) with active psoriatic arthritis were randomly allocated in a 1:1:1:1

236 Patients with active psoriatic arthritis were randomly allocated via interact

237 uble-blind, phase 3 study, 606 patients with psoriatic arthritis were randomly assigned in a 1:1:1 ra

238 ReA, 1 with rheumatoid arthritis, and 1 with psoriatic arthritis) were positive for C. trachomatis.

239 risk and improved prognosis of psoriasis and psoriatic arthritis, whereas gastric banding was not.

240 e data published in 2004 on the treatment of psoriatic arthritis, which arthritis affects 6 to 39% of

241 more effective than placebo in patients with psoriatic arthritis, which validates interleukin-17A as

242 In this trial involving patients with active psoriatic arthritis who had had an inadequate response t

243 that of placebo at month 3 in patients with psoriatic arthritis who had previously had an inadequate

244 valuated tofacitinib in patients with active psoriatic arthritis who had previously had an inadequate

245 valuated tofacitinib in patients with active psoriatic arthritis who previously had an inadequate res

246 t modalities are available for psoriasis and psoriatic arthritis, widespread treatment dissatisfactio

247 n inhibiting the symptoms and progression of psoriatic arthritis with less severe side effects.

248 The striking association of psoriatic arthritis with mutations in the killer immunog

249 and that proposed treatment of psoriasis and psoriatic arthritis with rituximab may result in unpredi

250 ithin this disease group and the relation of psoriatic arthritis with the other spondyloarthropathies

251 for spondyloarthropathy exist, the place of psoriatic arthritis within this larger group requires fu